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Background: Crohn’s disease (CD) is associated with elevated anti-glycans antibody response in 60% of CD
patients, and 25% of healthy first-degree relatives (HFDRs), suggesting a genetic influence for this humoral
response. In mice, anti-glucan antibody response depends on the NLRP3 inflammasome. Here, we explored the
effect of mutated CARD8, a component of the inflammasome, on anti-glycans antibody response in human.
Methods: The association between p.C10X mutation (rs2043211) of the CARD8 gene and the levels of anti-glycans
antibody response was examined in 39 CD families. The family-based QTDT association test was used to test for the
genetic association between CARD8 p.C10X mutation and anti-glycan antibodies in the pedigrees. The difference in
antibody responses determined by ELISA was tested in a subgroup of CD probands (one per family) and in a
subgroup of HFDRs using the Wilcoxon Kruskal Wallis non-parametric test.
Results: The QTDT familial transmission tests showed that the p.C10X mutation of CARD8 was significantly
associated with lower levels of antibody to mannans and glucans but not chitin (p=0.024, p=0.0028 and p=0.577,
for ASCA, ALCA and ACCA, respectively). These associations were independent of NOD2 and NOD1 genetic
backgrounds. The p.C10X mutation significantly associated or displayed a trend toward lower ASCA and ALCA
levels (p=0.038 and p=0.08, respectively) only in the subgroup of CD probands. Such associations were not
significant for ACCA levels in both subgroups of CD probands and of HFDRs.
Conclusion: Our results show that ASCA and ALCA but not ACCA levels are under the influence of CARD8
genotype. Alteration of CARD8, a component of inflammasome, is associated with lower levels of antibodies
directed to mannans and glucans at least in CD patients.
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In humans, the antibody response to glycans has been
associated with various infectious and autoimmune
diseases [1]. Regarding yeast glycans, monitoring of the
anti-mannan antibody response is used for the diagnosis
of invasive C. albicans infections [2]. Other anti-mannan
antibodies such as anti-S. cerevisiae antibodies (ASCA)
are associated with Crohn’s disease (CD) where they re-
present the most frequently found serological marker [3]* Correspondence: thierry.jouault@univ-lille2.fr
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reproduction in any medium, provided the orand at this time, the most related markers for early CD
diagnosis [4]. ASCA levels are elevated in 60% of CD pa-
tients and in 25% of their healthy first-degree relatives
(HFDRs) [5-7]. Although still unknown, one possible
origin for this antibody response would be an abnormal
adaptive response to the pathogenic yeast C. albicans
[8]. As well as ASCA, other specific serological markers
for CD have been described including anti-glucan (ALCA)
and anti-chitin (ACCA) antibodies [9], all of them being
generated during invasive C. albicans infection [10].
In this paper, we were interested in the role of caspase
activating and recruitment domain 8, CARD8, also known
as CARDINAL or TUCAN (tumor-up-regulated CARD-Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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anti-glycans antibodies response. CARD8 is a 48-kDa
peptide predominantly expressed in monocytes, pla-
centa, lymph nodes, and spleen. The CARD8 gene is lo-
cated at 19q13.3 between rs736289 and rs281379 loci
recently associated with CD in a GWAS meta-analysis
[11]. CARD8 has structural similarity with NOD1
(CARD4) and NOD2 (CARD15), whose mutations are
well known risk factors for CD [12]. CARD8 protein
functions as an inhibitor of apoptosis, by blocking
procaspase 9, as well as an inhibitor of NF-κB activation
[13] and it is a component of NLRP3 inflammasome
[14]. NLRP3 inflammasome (formerly cryopyrin, CIAS1,
and NALP3) is the best characterized inflammasome
complex. It includes ASC (apoptosis-associated speck-
like protein), caspase 1 and CARD8 [14,15]. NLRP3
inflammasome is activated by many microbial stimuli
and by endogenous danger signals such as ATP and
monosodium urate [15]. Other activators include indi-
gestible particulates like silica and alum [16] but also
fungal pathogens such as C. albicans [17-20].
Assembly of inflammasome proteins enables activation
of caspase 1 and, thereby, initiates the second danger
signal leading to the cleavage of the inflammatory cyto-
kine IL-1β into its biologically active form. IL-1β is in-
volved in animal models of fungal infection, together
with IL1-α and IL-18 [21-25]. However, there are now
strong evidences that it has a significant role in modulat-
ing the adaptive immune response [26,27]. Indeed, B-
cells are directly activated by β-glucans through NLRP3,
suggesting a critical role of B-cell-intrinsic NLRP3 for anti-
glycans antibody responses [19]. NLRP3 inflammasome is
thus considered to be a critical component for regulating
β-glucan-induced innate [19,28], but also adaptive immune
responses in mice [19]. In humans, multiple NLRs are
expressed in peripheral B lymphocytes, notably NOD1,
NOD2, NLRP1 and NLRP3 [29]. NOD2 and NOD1 genetic
variants together with their relationship with genetic sus-
ceptibility to Crohn's disease have been reported to be as-
sociated with anti-glycan antibody levels [30,31].
The deleterious mutation of CARD8 (p.C10X) pre-
dicting a stop codon at position 10, prematurely termi-
nates the protein. This mutation has consequences for
the protein’s function in both inflammasome-mediated
processes and NF-κB suppression. Several studies have
thus concerned the influence of the p.C10X variant of
CARD8 on the genetic risk of chronic inflammatory dis-
eases particularly CD. However, the results remain con-
troversial [32-36].
Given the participation of CARD8 in the NLRP3
inflammasome complex, the role of NLRP3 inflammasome
in the antibody response to yeast glycans, the structural
similarities displayed by the proteins encoded by the
CARD8, NOD2, NOD1 genes and their involvement inrelated pathways that modulate activation of immune cells
and inflammation, the aim of this study was thus to investi-
gate the relation between the p.C10X mutation of the
CARD8 gene and antibody response to yeast glycans. As
the p.C10X mutation was investigated in view of the anti-
body response to glycans in humans, we took advantage of
the well-characterized antibody response to yeast glycans
observed in families from Northern France with a strong
aggregation of CD cases.
Methods
Patients and study design
CD families were recruited from the EPIMAD Registry
[37]. Diagnosis of CD was based on the usual criteria, and
phenotypes were defined according to the Montreal classi-
fication [38]. A peripheral venous blood sample was
obtained from each participant at time of recruitment.
The study protocol was approved by the ethics committee
of the University Hospital of Lille, and informed written
consent was obtained from all study participants.
ASCA, ALCA and ACCA levels and genotypes at
rs2043211 were obtained for 200 subjects (87 men and
113 women) from 39 CD pedigrees, among them 76
subjects were affected with CD. A subgroup of one CD
proband per family and a subgroup of 39 HFDRs were
constituted. When several HFDRs were eligible in a
family, one HFDR was selected at random. A previous
reported panel of control families was used to determine
the allelic frequency of rs2043211 in a control popula-
tion from the same geographic area [30].
Genotyping
Genotyping for rs2043211, which consists of a T to A
transversion (c.30A > T) located at the third nucleotide
of codon 10 of CARD8, generating a premature stop
codon (p.C10X) and a severely truncated CARD8 pro-
tein, was performed by PCR-RFLP. Briefly, DNA was
extracted from whole blood using a QIAamp DNA
blood kit (Qiagen, Valencia, CA, USA) and amplified
with the forward primer 5'-GAGACAGAGGCAGAGC
CATT-3' and reverse primer 5'-CCCCTGAGTTCGATG
AAAAA-3'. The amplified fragment (175 bp) was then
digested with DpnI (New England Biolabs, Ipswich, MA,
USA), which recognizes the A allele, generating two frag-
ments 150 and 25 bp in size. The digestion products were
run on a 4% agarose gel. Ten DNA samples were also se-
quenced with the same primers used for amplification, to
verify the polymorphism. Genotypes at NOD2 (R702W,
G908R, 1007fs insC) and at the NOD1 +32656 loci were
determined using PCR-RFLP as previously described [30].
Detection of anti-yeast glycan antibodies
All sera were assayed using a panel of tests that detect
ASCA, ALCA and ACCA (IBDX; Glycominds, Lod,
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tigens: S. cerevisiae mannan, laminaribioside and chito-
bioside for the detection of ASCA, ALCA and ACCA,
respectively. Para-nitrophenyl derivatives of each antigen
were covalently bound to the surface of microtiter wells
using a linking agent (oligomer of 1,8-diamino-3,6-
dioxaoctan; Sigma Chemical Co., St. Louis, MO, USA).
These tests were performed according to the manufac-
turer’s instructions. Antibody levels were expressed in
arbitrary units (AU), relative to the manufacturer’s cali-
brators. The antibody titers for each sample were calcu-
lated by dividing the average optical density (OD) of the
sample by the average OD of the calibrator, multiplied
by the number of units denoted by the calibrator tube
label. Individuals were declared positive when levels of
antibody in their sera were superior to 50, 60 and 90 AU
for ASCA, ALCA and ACCA, respectively.
Statistical analyses
Fitting the Hardy-Weinberg equilibrium, allelic frequen-
cies and association with the disease were determined with
the Haploview software [39]. The family-based association
test implemented in the QTDT software [40] available at
(http://www.sph.umich.edu/csg/abecasis/QTDT/index.html)
was used to test for a genetic association between the
p.C10X mutation and a quantitative trait in the 39 pedi-
grees. In QTDT analyses, empirical robust p values were
obtained following 10,000 Monte Carlo permutations. The
CLUMP software [41] was used to compare allele frequen-
cies. As a classical Chi2 test the CLUMP software allows
comparison of frequencies between groups but a robust
significance is assessed using repeated Monte Carlo per-
mutations. Moreover, from the original 2 × 4 table (for the
4 groups of subjects) the CLUMP software clumps co-
lumns together in a new 2 × 2 table seeking to maximize
Chi2 value allowing assessment of post-hoc tests whose
robust significance is obtained using Monte Carlo permu-
tations. All CLUMP analyses were performed following
100 000 Monte Carlo permutations. When statistical in-
vestigations were not possible with the family-based asso-
ciation test implemented in the QTDT software, as there
were families with more than one member affected with
Crohn's disease, for a balanced influence of these families
in "classical" statistical analyses, a subgroup of one CD
proband per familiy was selected. Likewise for healthy re-
latives, a panel of one healthy relative selected at random
in each family was established. Comparison of antibody
responses was performed in the subgroups of CD pro-
bands and of HFDRs with the Wilcoxon Kruskal Wallis
non-parametric test. The Chi2 test was used to compare
the proportions of anti glycan positive subjects between
CD patients and healthy relative subjects (HFDR). All
"classical" statistical procedures were conducted with the
JMP Pro 9.02 software (SAS Institute, Cary, NC).Results
Distribution of the CARD8 p.C10X mutation (rs2043211)
in the CD families and in control populations
Allelic frequencies were not significantly different be-
tween the CD patients, the unaffected subjects (p=0.89)
of the 39 CD families, the subjects from French control
families and from the CEU panel of the HapMap version
3 release R2 (Table 1), but displayed a suggestive trend
of association as analyzed by the CLUMP software
(p=0.09). Post hoc tests disclosed that the chi2 was
maximal when clumping subjects from French control
families and HapMap subjects versus all subjects from our
CD families: CD patients and unaffected subjects (p=0.06).
There was a trend toward a lower frequency of the
CARD8 p.C10X mutation in the population from the CD
families as compared with reference (French control fa-
milies and HapMap CEU) Caucasian populations (Table 1).
However there was no association nor trend of association
between the p.C10X CARD8 mutation and localization
(L1, L2, L3, L4) and behavior (B1, B2, B3) of the disease
according to the Montreal classification (data not shown).
As anti-glycan antibody levels are well known to be
significantly higher in CD patients as compared to
healthy subjects, all analyses were adjusted according to
the affected/non-affected status.
CARD8 p.C10X mutation is significantly negatively
associated with ASCA levels in CD families
In familial transmission tests (QTDT) adjusted by the
CD status, including the whole population (n=200) the
p.C10X CARD8 mutation was significantly associated
with a lower ASCA level (p=0.024). As we previously
reported that ASCA levels were associated with the ge-
notypes at the NOD2 (R702W, G908R, 1007fs insC) and
at the NOD1 +32656 loci [30], QTDT analyses we ad-
justed according to the genotypes at the NOD2 and
NOD1 loci. Thus ASCA levels remained significantly as-
sociated with the CARD8 p.C10X mutation (p=0.023).
Similar QTDT results were obtained in CD families for
the association between the CARD8 p.C10X mutation
and the binary trait ASCA positive or negative according
to the 50 units threshold (Table 2).
In the subgroup of 39 CD probands, ASCA levels were
significantly lower according to the p.C10X genotype
(p=0.038, Figure 1A) in agreement with the above
reported familial QTDT analyses. In contrast, no signifi-
cant association could be detected between the p.C10X
CARD8 mutation and ASCA level in the subgroup of 39
HFDRs (p=0.64, Figure 1B).
CARD8 p.C10X mutation is significantly negatively
associated with ALCA levels in CD families
The results observed for anti-mannan antibodies (ASCA)
levels prompted us to perform similar analyses on the
Table 1 Allelic frequencies of the p.C10X mutation in the populations under study
p.C10X MAF 95% CI Comparison between the
4 groups (dof=3)
Comparison (dof=1) Comparison (dof=1)
1 CD patients 0.243 [0.183-0.316] p = 0.09 1 vs. 2 1+2 vs. 3+4
2 Healthy subjects from
CD families
0.238 [0.177-0.309] p=0.89 p = 0.06
3 French control families 0.347 [0.251-0.471] 3 vs. 4
p = 0.534 HapMap CEU 0.315 [0.271-0.361]
Frequencies are those determined in pedigrees using the Haploview software. All frequencies comparisons were performed with the CLUMP software and robust
p values were obtained following 100,000 Monte Carlo permutations. (MAF: minor allele frequency, dof: degree of freedom).
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with CD status and whose production was dependent on
inflammasome activation. In familial transmission tests
(QTDT) adjusted by the CD status, including the whole
population (n=200), the p.C10X CARD8 mutation was sig-
nificantly associated with a lower ALCA level (p=0.0035).
Likewise this association remained largely significant
following adjustment by the NOD2, NOD1 genotypes
(p=0.0034). Similar QTDT results were obtained in CD
families for the association between the CARD8 p.C10X
mutation and the binary trait ALCA positive or negative
according to the 60 units threshold (Table 2).
In the subgroup of 39 CD probands there was a trend
toward a lower ALCA level according to the p.C10X
genotype (p=0.08, Figure 2A). A similar analysis in the
subgroup of 39 HFDR, did not detect a significant asso-
ciation (p=0.38, Figure 2B).
ACCA levels are independent of CARD8 p.C10X mutation
In familial transmission tests (QTDT) adjusted by the
CD status including the whole population (n=200), no
association was observed between the p.C10X CARD8
mutation and the ACCA levels (p=0.577). Similarly, no
associations were detected in the subgroups of 39 CD pro-
bands and of 39 HFDR (p=0.95 and p=0.22, respectively).
Distribution of anti-glycans antibody responders in the
population examined
Considering the subgroup of one CD proband per pedi-
gree and the subgroup of HFDRs, anti-glycans antibody
levels (ASCA, ALCA) were elevated in CD probands as
compared with the group of healthy first-degree relativesTable 2 Results of familial QTDT analyses including the whole
Adjusted by the CD status
p value Z for mutated allele
ASCA level 0.024 −24.59
ASCA binary trait (positive/negative) 0.05 −0.146
ALCA level 0.0035 −17.08
ALCA binary trait (positive/negative) 0.0025 −0.232
The Z values reflect the strength of associations; negatives values reflect an associa
association with a higher level of the trait. NOD2, (R702W, G908R, 1007fs insC muta(HFDRs) in agreement with previously reported data
[5,6]: ASCA levels were 78.7±77.6 for CD probands and
24.1±27.0 for HFDRs (p<0.0001), ALCA levels 64.1±56.1
for CD probands and 26.4±20.0 for HFDRs (p=0.0002).
The proportion of anti-glycans antibody positive subjects
(Table 3) was in agreement with the data from the litera-
ture [5,6].
In the 39 CD probands subgroup there were less
ASCA positive patients (45.0%) in those having at least
one p.C10X CARD8 mutation (dominant model) than in
those being wild-type at this locus (63.2%). Although this
analysis on a limited number of subjects did not reach
significance (p=0.2) it was in agreement with familial as-
sociation results. Likewise in the subgroup of 39 CD
probands the ALCA positive CD patients were less fre-
quent (25.0%) in those with at least one p.C10X CARD8
mutation than in those who were wild-type (52.6%) but
this difference did not reach significance (p=0.07). The
proportion of CD patients being either ASCA or ALCA
positive were 50.0% in those having at least one p.C10X
CARD8 mutation versus 68.4% in the wild type ones
(p=0.2).
Discussion
This study investigated the relationships between a mu-
tation of the CARD8 gene encoding a component of
inflammasome and antibody response in humans in the
context of Crohn’s disease (CD) where anti-yeast glycan
antibodies are well documented. Our results show that
decreased levels of antibody to mannan (ASCA) and
Glucans (ALCA) but not chitin (ACCA) are associated
with the CARD8 p.C10X mutation. These results showpopulation (n=200)
Adjusted by the CD status, and NOD2 and NOD1 genotypes





tion with a lower level of the trait under study. Positive values would reflect












Figure 1 Measurement of anti-mannan antibody levels in human sera according to p.C10X genotype. Anti-mannan antibody (ASCA)
levels were determined in sera from CD probands (A) and healthy first-degree relatives (B) by ELISA. Antibody titers (expressed in AU according
to the reactivity of the manufacturer’s calibrator) in samples from subjects who were wild-type (C/C), heterozygous (C/X), or homozygous (X/X)
for the p.C10X mutation. Positive or negative ASCA status was determined according to the cutoff value of 50 AU determined according to the
manufacturer's instruction.
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sociated with Crohn's disease per se (at least in French
Caucasians) is associated with some but not all anti-
yeast glycan antibody levels (ASCA and ALCA but not
ACCA) in CD families.
Among several serological markers of CD, the anti-
glycan response has been shown to be one of the main
features of this disease [4,42]. The origin of this response
is still unclear although the possible involvement of C.
albicans has been proposed [8] and a link has been
shown between Candida colonization and ASCA [43].
Although high ASCA levels are considered to be
markers of CD (60% of CD patients are highly positive
for ASCA), it is unclear why some CD patients do not
have elevated ASCA levels independently of the gravity
of the illness or of its location.Figure 2 Measurement of anti-glucan antibody levels in human sera a
were determined in sera from CD probands (A) and healthy first-degree re
reactivity of the manufacturer’s calibrator) in samples from subjects who w
C10X mutation. Positive or negative ALCA status was determined accordin
manufacturer's instruction.Compelling evidence have led to the consensus that CD
is a multifactorial disorder that results from an uncon-
trolled inflammatory response to endoluminal microor-
ganisms in genetically predisposed individuals. To date,
over 70 distinct genomic loci have been shown to confer
susceptibility for CD [11]. Most of them encode or are lo-
cated in the vicinity of genes that are involved in the in-
flammation process, the modulation of host-microbe
interactions and in the maintenance of epithelial homeo-
stasis in the gut. The most strongly association with CD
has been shown for the gene coding the innate pattern
recognition receptor NOD2/CARD15 [12]. However, other
genes such as CARD8, located at an IBD locus, have also
been shown to be involved in CD [35,36].
CARD8 is a protein whose function has not been fully
elucidated. It is involved in regulation of pro inflammatoryccording to p.C10X genotype. Anti-glucan antibody (ALCA) levels
latives (B) by ELISA. Antibody titers (expressed in AU according to the
ere wild-type (C/C), heterozygous (C/X), or homozygous (X/X) for the p.
g to the cutoff value of 60 AU determined according to the
Table 3 Proportion of anti-glycans antibody positive subjects among the CD probands and the HFDRs
ASCA positive ALCA positive ASCA or ALCA positive
n % 95% CI p value n % 95% CI p value n % 95% CI p value
CD probands (n=39) 21 53.8 [38.6-68.4] p<0.0001 15 38.4 [24.9-54.1] p=0.0008 23 58.9 [43.4-72.9] p<0.0001
HFDR (n=39) 4 10.3 [4.1-23.6] 3 7.7 [2.7-20.3] 6 15.4 [7.3-29.7]
ASCA positivity was according to the 50 AU threshold and ALCA positivity according to the 60 AU threshold.
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as a susceptibility gene for CD [34]. However, the associ-
ation between CARD8 and CD remains controversial
[44,45] although the influence of NFκB in ASCA produc-
tion has been reported [46]. CARD8 also participates to
the formation of inflammasome NLRP3 [14,15] involved
in innate immunity, thus impacting the cellular response
based on caspase-1 and NFκB [47]. Using NLRP3 knock-
out mice, inflammasome has been shown to be important
in production by phagocytic cells of IL-1β [19], a cytokine
important in inflammatory processes and involved in the
modulation of the adaptive immunity [48,49]. NLRP3 also
plays a role in the adaptive immunity since it is implied in
B-cell activation leading to production of anti-glycans
antibody, in a manner independent of the innate immu-
nity [19].
In agreement with the literature [44], our current re-
sults showed that the CARD8 mutation was not asso-
ciated with CD in our panel of French families. On the
other hand, the p.C10X allele was associated with a signifi-
cantly lower antibody response with respect to glycans
which are present on the surface of yeasts. Surprisingly,
such association was not evidenced for antibody response
directed against chitin, a wide spread component,
highlighting a difference in either antigen presentation or
regulation according to glycans. This is in accordance with
the observation that B-cells from NLRP3 knockout mice
are unable to produce antibodies after stimulation by glu-
cans [19] suggesting that production of anti-glucan anti-
bodies by B-cells is at least partly dependent on the
activity of inflammasome. Although the putative biological
link between the p.C10X mutation and the anti-glycans
antibody response remains to be clarified these results
represent the first clue as to a relationship between innate
and adaptive immunity in CD.
B-cells may be directly activated by glycans [50]. How-
ever, B-cell may also be activated by neutrophils through
the production of the B-cell specific cytokine (BAFF)
allowing natural immunoglobulins production by B-cells
[51,52]. We previously reported that +32656 NOD1
insertion-deletion polymorphism associates with unre-
sponsiveness towards glycans [30]. NOD1/CARD4 is an
intracellular sensor for peptidoglycan from Gram-negative
bacteria that plays an important role in neutrophil func-
tion, recruitment and activation [53]. Considering the role
that NOD1 plays on neutrophils activation, which in turnmay result on the alteration of B-cells activation and anti-
body production, we thus examined the possible relation
between NOD1 polymorphism and CARD8 p.C10X muta-
tion toward anti-glycans antibodies production. CARD8 p.
C10X mutation and +32656 NOD1 insertion-deletion
polymorphism did not show any additive participation to
anti-glycans modulation and CARD8 mutation by itself
associated with antibody production phenotype. Thus our
observations suggest that CARD8 and NOD1 genetic va-
riants independently associate with antibody levels through
independent pathways without any detected additivity.
HFDRs analyzed separately did not show any signifi-
cant association between ASCA, ALCA or ACCA and
the CARD8 p.C10X mutation. However we cannot ex-
clude that the low antibody levels observed in HFDRs
make difficult the detection of a significant difference
according to genotype, especially with a limited sub-
group of subjects.
Severity of CD is associated with higher ASCA and
ALCA levels [54,55]. This suggests a possible involve-
ment of inflammasome in: (i) the production of pro-
inflammatory cytokines such as IL-1β and secondarily
IL-17 leading to the development of the CD inflamma-
tory process [56,57]; and (ii) an effective anti-glycan re-
sponse [19]. CARD8 has been shown to regulate NFκB-
dependent cell activities, it is thus anticipated that the
absence of active CARD8, evidenced by an altered ASCA
response, could be associated with a more favorable
prognosis in terms of disease evolution. Here, we were
unable to detect a significant association between the
genetic alteration of CARD8 and the severity and loca-
tion of the disease according to the Montreal classifica-
tion [38].
Conclusions
The main result of our study is that decreased levels of
anti-yeast glycan antibody levels are associated with the
CARD8 p.C10X mutation in the families under investi-
gation. Associations may be considered as confident as
they were based on QTDT analyses including the whole
population under study (200 subjects). Regarding the
stratifyed analyses in the subgroup of 39 patients pre-
senting Crohn's disease and of 39 healthy relatives, re-
sults may be interpreted with caution regarding the low
number (39) of subjects included in the analyses. It is
likely that CD affected patients have a major weight in
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can antibody difference association with CARD8 p.C10X
in the healthy relatives subgroup may reflect a lack of
statistical power. Despite not being directly associated
with Crohn's disease (at least in French Caucasians) the
CARD8 p.C10X mutation, which is thought to affect
regulation of inflammasome activity, is specifically asso-
ciated with some anti-yeast glycan antibody levels (ASCA
and ALCA) in CD families. Confirmation of a mechanistic
role of CARD8 in anti-glycan antibody production may be
important in better understanding the participation of
inflammasome in adaptive response in particular against
yeast components, but also for individual diagnosis in the
case of patients presenting CARD8 mutation for whom
ASCA levels would be low whatever the gravity of their
disease.
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